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Abstract
Asthma represents a growing health, social, and economic issue as it affects a considerable part of the population, adversely 
affecting patients’ quality of life, while its chronic character and severity of symptoms impair family life. It has been estimated 
that 12% of the population of Poland (4.5 million) suffer from asthma and 16% report wheezes (5.7 million). In order to improve 
asthma care and patient outcomes, evidence-based recommendations must not only be developed, but also disseminated and 
implemented at a national and local level, which is key for integration into clinical practice. For these reasons, the Polish Society 
of Allergology (PSA) has decided to undertake actions, leading to some improvement of the epidemiological situation in Poland. 
The Polish National Programme of Early Diagnosis and Therapy of Asthma has been developed. This initiative is a response to the 
demand for medical care improvement in patients with asthma. Its goals include early diagnosis of asthma and improved control 
in the course of the disease, a reduction in the number of subjects with asthma-associated disability for work, an increased use 
of anti-inflammatory agents vs. rescue medications, a reduced number of patients with severe, uncontrolled bronchial asthma 
and prevention of complications of the disease and of adverse effects of applied therapy, an increase in social awareness regar-
ding the bulk of problems associated with asthma, and reduction of the total costs of the care of patients suffering from asthma. 
Details regarding programme assumptions, goals, target groups, and modes of implementation are described in the document. 
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Streszczenie
Astma oskrzelowa stanowi rosnący problem zdrowotny, społeczny i ekonomiczny. Choroba ta w istotny sposób wpływa na jakość 
życia pacjenta, ze względu na przewlekły przebieg i nasilenie objawów upośledza aktywność i życie rodzinne. Badania epidemiolo-
giczne wykazały, że w Polsce na astmę cierpi około 12% populacji (4,5 miliona osób), a 16% populacji (5,7 miliona) zgłasza świsty. 
W celu poprawy jakości opieki nad pacjentami nalezy nie tylko tworzyć zalecenia oparte na wynikach najnowszych badań, ale 
również dbać o rozpowszechnienie i implementację nowych standardów w codziennej praktyce. Z tego powodu Polskie Towarzy-
stwo Alergologiczne (PTA) wystąpiło z inicjatywą opracowania Polskiego Narodowego Programu Wczesnej Diagnostyki i Terapii 
Astmy. Inicjatywa ta jest odpowiedzią na potrzebę poprawy jakości opieki medycznej nad pacjentami z astmą. Cele Programu 
obejmują wczesne rozpoznanie choroby, poprawę kontroli astmy, spadek liczby dni niezdolności do pracy z powodu astmy, wzrost 
stosowania leków kontrolujących w stosunku do leków ratunkowych, spadek liczby pacjentów z ciężką, trudną do leczenia posta-
cią astmy, spadek powikłań wynikających z potencjalnych efektów ubocznych terapii, wzrost świadomości społecznej problemu 
astmy, a w konsekwencji spadek kosztów opieki nad pacjentami z astmą. Poniższe opracowanie przedstawia szczegóły założeń 
Programu, jego cele, grupy docelowe i metody działania. 
Słowa kluczowe: astma oskrzelowa, plan działania, wczesna diagnostyka, terapia astmy
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Asthma as a global health, social,  
 and economic issue
The number of patients suffering from asth-
ma has doubled during the last ten years. The 
World Health Organisation (WHO) assumes that 
300 million people all over the world are now 
affected by this disease, while the incidence of 
asthma will continue to rise, involving a further 
100 million patients by the year 2025 [1]. In Eu-
rope this disease affects 30 million people, amo-
unting for as much as 40% of subjects in certain 
populations [2]. The growth of asthma incidence 
has changed its meaning in the hierarchy of social 
health demands. At present, asthma is perceived 
in many countries as a serious health, social, and 
economic issue as it affects a considerable part 
of the population, adversely affecting people’s 
quality of life, while its chronic character and 
severity of symptoms impair family life and 
constrain the professional and social activity of 
affected patients [3, 4]. Thus, asthma is, in certain 
countries, the most frequent cause of disability in 
work and is the most frequent chronic disease in 
children and the most common reason for their 
absence from school. Asthma also quite often 
requires therapy in a hospital environment. The 
WHO estimates that every year 25 million disa-
bility-adjusted life years (DALYs) are lost because 
of asthma. Every year, 255 thousand people die 
from asthma [1], i.e. one per all 250 deaths in the 
world results from asthma. In Europe, one man 
dies from asthma every hour, and 90% of these 
death cases could have been prevented by having 
improved medical care and reducing exposure to 
risk factors [2].
The annual asthma-related costs in the Eu-
ropean Union amount to approximately EURO 
17.7 billion, while the loss of production capacity, 
resulting from poor asthma control, costs Europe 
EURO 9.8 billion per year [2]. Finnish studies have 
demonstrated that the treatment of patients suffe-
ring from severe asthma is 13 times more expen-
sive than in the mild course of this disease [5]. 
Therefore, the expenses born with regard to the 
treatment of patients with severe asthma, i.e. 20% 
of the total number of patients suffering from this 
disease, consumed 60% of all the funds allocated 
for asthma therapy. These figures result from 
high costs of hospitalisation. In the USA, they 
stand for as much as 51.2% of the direct costs 
of asthma therapy, 10.5% referring to first-aid, 
18.4% reflecting the costs of outpatient therapy, 
and 19.9% resulting from drug reimbursement [6]. 
Beside the direct costs of medical treatment, asth-
ma is a cause of high economic (i.e. non-medical) 
costs, including those associated with the follo-
wing: the loss of production capacities, sick leave, 
disability pensions, nursing benefits, etc. [7]. 
The indirect costs are much higher than the direct 
ones, although they are rarely considered in the 
general social awareness. 
With regard to the alarming epidemiologi-
cal situation, the Global Initiative for Asthma 
(GINA) has been established under the auspices 
of the WHO and NHLBI, gathering experts from 
all over the world [8]. The main task of this 
organisation was the development, and then 
continuous updating, of the guidelines for asth-
ma diagnostics and therapy. The latest update 
of GINA (issued May 6, 2014) points out that in 
order to improve asthma care and patient out-
comes, evidence-based recommendations must 
not only be developed, but also disseminated 
and implemented at a national and local level, 
which is key to integration into clinical prac-
tice. It has been noted that recommendations 
for implementing asthma strategies are based 
on successful programs worldwide, and that 
implementation requires an evidence-based 
strategy taking into account local cultural and 
socioeconomic conditions [8]. However, it appe-
ars from the studies performed in France [9] that, 
despite the existence of the guidelines, as many 
as 66–86% of patients with bronchial asthma 
are improperly treated: 62–84% of patients with 
severe asthma do not receive any anti-inflam-
matory agents. These patients are particularly 
exposed to recurring, severe exacerbations of 
asthma, often demanding hospital care. High 
sick-leave absence rates at work and school are 
observed in this group of patients, while the risk 
of death is also higher among these patients. 
In the international AIRE study in 1999 [10], 
only 5.1% of adult respondents achieved the 
targets of effective asthma treatment as defined 
by GINA. Only 23% of the studied subjects used 
inhaled glucocorticosteroids, and only 41% of the 
respondents had used anti-inflammatory drugs 
during the last 4 weeks, while rescue drugs were 
used by 2/3 of the studied population. If asthma 
is not properly controlled, it considerably limits 
the patient’s life activity, significantly impairs the 
quality of life, and may also become a life-thre-
atening condition. The defined and published 
standards of management, dedicated to persons 
suffering from asthma, will not be effective if 
they are not applied in everyday healthcare prac-
tice. Meanwhile, as it appears from performed 
studies, asthma is not properly diagnosed, phy-
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sicians improperly evaluate the required degree 
of asthma control and recommend inappropriate 
therapy, and patients do not know how to use 
their inhalers and do not adhere to medical re-
commendations. All of this leads to poor asthma 
control, disease progression to its severe forms, 
the necessity of frequent emergency interven-
tions, frequent hospitalisations, life threatening 
attacks, and even deaths from asthma.
The epidemiological situation in Europe 
has become the subject of analysis performed by 
a group of experts from the Centre for European 
Policy Studies for the Asthma, Allergy, and In-
flammation Research Group, appointed within the 
6th Framework Programme of the European Union. 
It recommends that EU Member States develop 
integrated programmes of asthma management. 
Such a plan [11] was earlier implemented in Fin-
land, resulting in better accessibility to medical 
care, improved care of patients with asthma, 
earlier diagnosis of the disease, a decrease of 
the number of patients suffering from the severe 
forms of the disease, and, despite the increased 
number of patients, a reduction in the total costs 
of care by more effective control of the disease, 
allowing for much lower expenses for emergency 
conditions and patient disability consequences. 
Intensive works are underway to develop and 
implement similar plans in other countries of the 
European Union.
Why do the Polish citizens need the programme?
The problem of the rapid increase in the 
incidence of asthma and other allergic diseases 
was noted by the Polish Society of Allergology 
in the 1990s. At that time, the first national ep-
idemiological study of the prevalence of atopic 
diseases in Poland (PMSEAD) was designed and 
undertaken [12]. The prevalence of bronchial 
asthma in Poland was estimated at the level of 
8.6% (95% CI: 7.7–9.6) in children and 5.4% 
(95% CI: 5.0–5.8) in adult patients [13]. In 2005 
ECAP, another national epidemiological study, 
was started, and the initial results confirmed 
a higher incidence of asthma in urban areas [14]. 
It has been found that allergies affect about 40% 
of Polish citizens (14.4 million inhabitants), with 
the most frequent being allergic rhinitis (25%, 
9 million inhabitants) followed by asthma (12%, 
4.5 million inhabitants). Moreover, smoking 
has been identified as a serious social problem 
associated with allergic diseases [15]. Similarly, 
in the COPD cohort 57% of patients admitted 
current smoking and 43% declared smoking 
in the past. The negative impact of smoking 
on family relations was declared by 16.4% of 
respondents [16]. 
In Łódź, the highest incidence rates of asthma 
were found in the city-centre area, being 3-times 
higher than those in agricultural areas [17]. 
Moreover, the results of the study revealed short-
comings in the healthcare system. Forty-eight per 
cent of adult asthma sufferers had not used any 
antiasthma medication in the previous 12 months, 
and the most commonly used medications were 
beta(2) agonists (46.8%), inhaled glucocorticoste-
roids (36.4%), and xanthine derivatives (33.8%). 
Insufficient control of asthma in patients is 
a problem in Poland. In the AIRCEE (Asthma In-
sights and Reality in Central and Eastern Europe) 
study published in 2004, evaluating the degree 
of disease control in patients suffering from 
asthma, more than 70% of respondents reported 
diurnal symptoms of bronchial asthma at least 
once a week, while 20% experienced them every 
day. Almost 18% of the studied subjects were 
hospitalised during the last year of the study, 
and almost half of them had to seek immediate 
medical care. Almost 50% of the patients received 
diastolic agents, and only 27% were treated with 
inhaled glucocorticosteroids [18]. In Poland, in 
2006, there were approximately 58 thousand 
hospital admissions because of asthma, includ-
ing 5 thousand cases with a direct threat to the 
patient’s life because of status asthmaticus. The 
average required period of hospitalisation in cases 
of asthma is 8 days, extending to 12 days for status 
asthmaticus [19].
For these reasons, the Polish Society of Al-
lergology has decided to undertake actions in 
an attempt to see some improvement in the ep-
idemiological situation in Poland. The National 
Programme of Early Diagnostics and Therapy of 
Bronchial Asthma has been developed by the 
initiative of the PSA’s President. This initiative 
is a response to the demand of medical care 
improvement in patients with asthma. Its goals 
include early diagnosis of asthma and improved 
control in the course of the disease, a reduction 
in the number of subjects with asthma-associated 
disability for work, increased use of anti-inflam-
matory agents vs. rescue medications, a reduced 
number of patients with severe, uncontrolled 
bronchial asthma, prevention of complications 
of the disease and of adverse effects of applied 
therapy, an increase in social awareness regarding 
the bulk of problems associated with asthma, and 
a reduction of the total costs of the care of patients 
suffering from asthma. 
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Programme assumptions and goals
One of the most burning problems regar-
ding the medical care of patients with bronchial 
asthma is the failure to diagnose the disease. 
The latest epidemiological studies indicate that, 
despite the international publications (GINA) 
and national standards of management, only 
approximately 30–40% of patients are property 
diagnosed. Underdiagnosis results in delayed 
implementation of effective treatment and, con-
sequently, in the development of more severe 
forms of the disease, demanding a higher number 
of ambulance interventions and hospitalisations. 
The basic assumptions of the National Programme 
of Early Diagnostics and Therapy of Bronchial 
Asthma include an increased identification of 
bronchial asthma, both in children and in adults 
and, as a direct consequence of early diagnosis, 
conformity with standards and early administra-
tion of appropriate treatment protocols, including 
anti-inflammatory drugs (Tab. 1). 
Early diagnostics and treatment will prevent 
the development of irreversible functional di-
sorders of the respiratory system (asthma is the 
second greatest risk factor of developing chronic 
obstructive lung disease, after exposure to tobacco 
smoke), will reduce the number of severe cases 
of the disease, including mortal ones, reduce the 
number of disability pensions that result from 
asthma, and will reduce the costs of care applied 
to patients with bronchial asthma. The goal of the 
Programme is not a design of any new standards 
of management but a general improvement of the 
medical care of asthmatic patients with a decre-
ase of its costs by implementation of the actual 
recommendations in everyday practice, based on 
scientific evidence, international recommenda-
tions, and national groups of experts. This Pro-
gram is part of the Global Alliance against Chronic 
Respiratory Disorders (GARD), an international 
strategy implemented under the protectorate of 
the World Health Organisation (WHO). The Pro-
gramme has been dedicated to GPs and will be 
performed along the guidelines of the Practical 
Approach to Lung Health (PAL) strategy.
Target groups
Implementation of the programme will 
involve all the persons who participate in the 
care of asthmatic patient as well as those having 
contact with the patients. In particular, the pro-
gramme is dedicated to primary care physicians 
and paediatricians. Nurses and pharmacists 
should also be involved in the active care and 
education, as they may increase the effective-
ness of the therapy by education and control of 
patients’ compliance with recommendations. 
In time, the programme is to be extended to 
other physicians/specialists who have contact 
with asthmatic patients. It is also important to 
strengthen the role of these specialists as experts 
in the diagnostics and therapy of patients suf-
fering from asthma.
Primary care physicians (PCPs)
Early suspicion of bronchial asthma and 
consideration whether further diagnostics is 
appropriate and justified are the dilemmas of 
a primary care physician and not of a specialist 
in a clinical environment. For this reason, PCP 
is the main target group for the programme, 
to which educational activities are dedicated. 
The assumption of the programme is increased 
identification of asthma and the earliest possible 
administration of proper treatment. Properly 
trained primary care physicians (PCPs), familiar 
with the standards of therapeutic management, 
should have an opportunity to diagnose asthma 
at reference diagnostics centres. Diagnostic 
specialist centres ensure high and repeatable 
quality of tests and studies. The medical care of 
milder forms of bronchial asthma should be left 
to the management of PCPs. Any doubtful cases, 
severe forms of bronchial asthma, hypersensiti-
vity to drugs, or therapeutic failures should be 
referred by PCPs to specialist outpatient clinics. 
This will decrease the costs of care of asthmatic 
patients.
Table 1.  Basic assumptions of the Programme of Early 
Diagnostics and Therapy of Bronchial Asthma  
in Poland
Goals of the National Programme of Early Diagnostics and 
Therapy of Asthma
1. Early diagnosis of asthma
2. Better pharmacological control:
 a. reduced number of hospitalisation days because of asthma
 b. decreased mortality rates because of asthma
 c. reduced number of persons with asthma-related disability  
        for work
increased use of anti-inflammatory vs. symptomatic drugs
3. Reduced number of patients with severe, uncontrolled  
bronchial asthma
4. Prevention of disease complications and adverse effects  
of therapy
5. Higher social awareness regarding the problems associated 
with asthma
6. Reduction of the total costs of care of patients with asthma
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Paediatricians
Diagnosis of bronchial asthma in children 
is a difficult task, especially in the youngest age 
groups, where viral infections with obturation 
are frequently observed. Therefore, the advising 
of education in this group of physicians is clear 
and unquestionable.
Nurses
The basis for effective care of patients suffe-
ring from chronic diseases is regular education 
and the control of adherence to physician’s recom-
mendations. The role and potentials of nurses are 
now rather underestimated in Poland. The tasks 
of properly trained nurses may include patient 
education concerning the proper use of inhalation 
drugs, peak-flow meter operations, and training 
in recommended procedures in case of disease 
exacerbation, following individual management 
protocols that should have been earlier designed 
with the physician.
Pharmacists
A significant practical problem in the care of 
patients with bronchial asthma concerns errors 
in the use of inhalation drugs, the effect being 
limited efficacy of the applied therapy. The main 
educational task for the pharmacists will be the 
promotion of the proper use of drugs administered 
via inhalers. Additionally, they could control the 
proportions of administered symptomatic and 
disease-controlling drugs, as well as promoting 
simple tests evaluating the actual degree of asth-
ma control, basic measurements of the respiratory 
system efficiency (PEF, peak expiration flow), 
plans of management in cases of disease exacerba-
tions, and encouraging sufferers to visit a doctor 
when necessary (including cases of increased use 
of rescue drugs). 
Obstetricians
A problem often faced in our everyday prac-
tice is insufficient knowledge regarding the safety 
of drug usage in pregnant women, also those 
with bronchial asthma. Sometimes, all inhalation 
drugs are withdrawn, leading to asthma exacer-
bations and significant complications. The goal 
of the programme is to provide obstetricians with 
the necessary knowledge on the safety of anti- 
-asthmatic drugs in gestation.
Patients with asthma and society
Basic information concerning bronchial 
asthma should be provided to affected patients, 
as well as distributed in the whole of society. 
Educational activities should be developed in 
close cooperation and as an answer to goals 
identified by patients’ organisations. One of the 
goals of the Programme should be the effective 
elimination of the stigmatisation of patients 
with diagnosed asthma. An important message 
is such that bronchial asthma is, in fact, a chro-
nic disease, but proper adherence to prescribed 
therapy usually ensures effective control of 
asthmatic symptoms. Among patients with the 
diagnosed disease, education is very impor-
tant, concerning the necessity of regular use of 
recommended drugs, the way of application of 
inhalation drugs, and the propagation of recom-
mended procedures in cases of exacerbation. It 
is advisable to provide information concerning 
the safety of inhalatory glucocorticosteroids, 
as steroidophobia is a significant problem in 
everyday practice and may be responsible for 
worse patient compliance with physicians’ 
recommendations. Some information about 
asthmatic symptoms, targeted towards groups 
at increased risk, especially to allergic patients 
and patients with allergic rhinitis, will result in 
better detectability of the disease.
The role of specialists
Local specialist centres will be the main 
link in the educational network, which will be 
the base for the programme. Because of the scale 
of the programme in Poland, the first training 
sessions, propagating the programme ideas, will 
be held at the largest units in academic centres 
and big cities. They should provide the base for 
reference diagnostic centres (minimal basic dia-
gnostics includes spirometry, provocation tests, 
and skin tests) to be available for patients referred 
by PCPs. In subsequent stages these centres will 
become the framework for local training networks 
dedicated to PCPs. The division of tasks of PCPs 
and specialists in the care of patients with bron-
chial asthma will be developed in collaboration 
between specialists and PCPs in one of the appo-
inted working groups.
Activity areas
The programme has been addressed to socie-
ty and to the medical environment; therefore, the 
activities have been configured on these planes. In 
order to ensure the programme’s effective imple-
mentation, the involved organisational units will 
enter collaboration with medical environments, 
patient environments, media, governmental, and 
non-governmental organisations. 
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The main tasks of the programme include 
propagation of basic knowledge on asthma in so-
ciety and intensive training sessions of physicians 
to improve their qualifications and, consequen-
tly, the quality of care provided to patients with 
asthma. The programme is dedicated directly to 
society and to physicians, but first of all to pri-
mary care physicians (PCPs). Education is to be 
at the base of all the undertaken actions. Training 
sessions and events will be held by specialists 
who provide care to patients suffering from 
asthma. The organisation of regional specialist 
centres for the care of patients with asthma is 
to facilitate a closer collaboration between PCPs 
and specialists in allergology and pulmonology. It 
will also provide assistance to other specialists, to 
whom asthmatic patients are referred with other 
health problems. 
Active collaboration will be undertaken with 
the National Healthcare Fund regarding the im-
plementation of changes in the actual healthcare 
system, to improve the care of asthmatic patients 
and to more effectively utilise the funds allocated 
for this purpose.
Programme implementation tools
The implementation of guidelines concerning 
the diagnostics and therapy of asthma requires 
application of appropriate means (Tab. 2). The 
basis for the implementation shall be a series 
(2–3) of short (approximately 2-hours) training 
sessions delivered either on-site at the location 
of the audience’s work or at the reference centres 
for small groups of participants. Other forms of 
knowledge promotion and distribution will inc-
lude symposia and conferences devoted to the 
programme, or dedicated sessions during other 
conferences of societies/associations of doctors, 
nurses, midwives, and pharmacists. Oral presen-
tations require printed and audio-visual aids to 
be better understood and remembered. Necessary 
materials will be prepared for each target group, 
taking into account their specific character and 
range of activities.
Programme structure
The programme is being developed under 
the auspices of the Polish Society of Allergology 
(PSA) by the initiative of the PSA’s President, 
who, together with other authors, brought up the 
initial idea of the programme. The PSA’s Presi-
dent, following positive results of the programme 




— Council for Evaluation of the Programme 
Implementation.
The Commission for Evaluation of the Pro-
gramme Implementation shall be appointed by 
the Board of the Polish Society of Allergology as 
an organ independent of the Executive Commit-
tee. Its tasks shall include:
— evaluation of the effectiveness of the Pro-
gramme implementation,
— evaluation of the Programme outcomes,
— advisory role towards the Executive Commit-
tee and the Working Groups of the Executive 
Committee.
For details regarding the programme structure 
see Figure 1.
Programme goals — modes of accomplishment
The ways to accomplish the goal of early asth-
ma diagnosis are presented in Table 3. In order to 
see information about detailed modes of action to 
improve asthma control, reducing the number of 
patients with poor asthma control, educating pa-
tients in proper inhalation techniques, reducing 
the number of patients with severe, uncontrolled 
asthma, preventing disease complications and 
side effects of therapy, increasing awareness of the 
problems associated with asthma among society 
and policy makers, reducing the costs of asthma 
care, please see the full version of the POLASTMA 
programme available online (www.mojaastma.
org.pl or www.pta.med.pl). 
Table 2.  Chief action methods within the National  
Programme of Early Diagnostics and Therapy  
of Bronchial Asthma
Chief action methods within the National Programme of Dia-
gnostics and Therapy of Bronchial Asthma
1. Promotion of diagnostic and therapeutic management, in 
adherence with standards based on scientific evidence
2. Extension of educational networks based on local specialist 
centres
3. Training coverage of key target groups: PCPs, paediatricians, 
nurses, pharmacists, obstetricians 
4. Educational coverage of patients and of the whole of society
5. Unification of diagnostic methods, creation of local diagnostic 
reference centres, available for PCPs
6. Promotion of therapy of disease exacerbations, based on indi-
vidual management plans
7. Education in the proper use of inhalation drugs
8. Promotion of healthy lifestyles, including the fight with  
tobacco smoking addiction
9. Promotion of research on bronchial asthma
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Figure 1. Operational structure of the Polish National Programme of Early Diagnosis and Therapy of Asthma (POLASTMA)




1. Improvement of early asthma diagnosis at the primary care level
2. Distribution of general information on asthma among physi-
cians of other specialties
3. Distribution of general information on asthma in broad society
Activities:
1. Education of primary care physicians
2. Design of the bronchial asthma diagnostic algorithm for PCPs
3. Extension of the range of tasks of PCPs, regarding diagnostics
4. Increasing the availability of spirometric and allergological 
tests for PCPs
5. Preparation of press releases on asthma for social needs and 
active involvement in its propagation in the mass media 
6. Support of patient organisations in propagating knowledge 
about asthma
7. National social actions, e.g. organisation of World Asthma Day 
Tools:
1. Training sessions for physicians concerning asthma diagno-
stics (including the interpretation of spirometric tests)
2. Symposia and conferences devoted to diagnostic problems in 
asthma
3. Brochures
4. Algorithms of asthma diagnostics developed for the needs of 
primary care
5. Training of nurses in spirometric tests
Programme implementation assessment
A precisely scheduled and repeated evaluation 
of particular training sessions/events at the local le-
vel will be the basis for the assessment of efficiency 
of all the actions undertaken within the programme. 
In subsequent years, an evaluation of the final pro-
gramme stages will be absolutely crucial.
Evaluation of programme development 
and training efficacy
Every training session/event should be pre-
ceded by a short test, checking the knowledge of 
participants regarding the discussed issues. The 
same test should be repeated after training. The 
test results should be sent to participants and 
filed at the Programme Office for further analy-
sis. After each training session, the participants 
should be given the possibility to evaluate the 
quality of training, lecturers, and materials and 
to propose new subjects that are important for 
their everyday practice.
Evaluation of the programme results in 
subsequent years
It will be necessary for correct evaluation of 
the programme results in order to create a data-
base with data describing selected parameters 
at their initial stage, followed by an evaluation 
of these parameters in subsequent years of the 
programme’s duration. It will be necessary to 
start collaboration with organisations that are 
involved in the acquisition of data necessary for 
programme evaluation and to obtain access to 
the required data. Evaluation of the programme 
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Table 4. Executive summary of POLASTMA — the National Programme of Early Diagnostics and Therapy of Asthma
Knowledge 
about asthma
1. Asthma as a civilisation disease — often diagnosed in developed countries, while its incidence rapidly grows in develo-
ping countries as well
2. Patient care costs have been growing
3. Evidence for inflammatory background of the disease
4. State-of-the-art therapy ensures proper control of the disease
National  
problems
1. Asthma in Poland occurs in 10% of children and 6% of adults 
2. It is often an unidentifiable disease — even as many as 70% of affected children are not properly diagnosed and,  
consequently, not property treated 
3. Symptomatic drugs are overused in the therapy of asthma, while anti-inflammatory agents of disease suppressing  
character are taken too rarely 
4. Asthma is a frequent cause of absence at work and school and is at the basis of high disability rates 
5. Untreated or poorly treated asthma leads to the development of chronic obturative lung disease
6. Asthma is perceived as a disease that impairs normal life (an obstacle in normal life) 
Strategy 1. Making the persons who are responsible for healthcare policy aware that asthma in Poland is a serious health, social, 
and economic problem 
2. Design and implementation of the National Programme of Early Diagnostics and Therapy of Asthma, oriented towards:
a) prevention of asthma
b)  early diagnostics
c)  therapy adjusted to actual patent needs
d) improved care of patients with severe, difficult-to-treat asthma
e) restoring the ability of affected patients to take part in school activities or work 
f) prevention of disease complications and of therapy side effects 
g) popularisation of knowledge on asthma in society 
Goals 1. Early diagnosis of asthma
2. More effective pharmacological control:
a) to reduce the number of hospitalisation days because of asthma 
b) to reduce the mortality rates because of asthma 
c) to reduce the number of persons disabled from work by asthma 
d) to increase the use of anti-inflammatory drugs vs. symptomatic drugs
3. To reduce the number of patients with severe, uncontrolled bronchial asthma
4. Prevention of disease complications and of therapy side effects
5. To increase social awareness regarding the problems associated with asthma
6. To reduce the total costs of care of asthmatic patients
Tasks 1. To increase the awareness among physicians of the inflammatory background of asthma and to propagate  
anti-inflammatory therapy
2. Development of a bronchial asthma diagnostic algorithm for primary care physicians 
3. Development of simple guidelines for the therapy of asthma and its exacerbations
4. Extension of tasks of PCPs, regarding the diagnostics and therapy of asthma
5. Propagation of simple asthma control tools
6. To increase the availability of spirometric and allergological tests for pcps
7. To create a system of interdisciplinary care of asthmatic patients (including the care of pregnant women with asthma)
8. To define standards of care for patients with severe, difficult-to-treat asthma
9. To develop rehabilitation programmes, restoring the ability to work
10. To define and extend the role of nurses in the care of patients suffering from asthma
11. To increase the patient’s role in the therapeutic process
12. Patient education at each stage of contact with medical personnel, including pharmacists 
Activities Implementation of guidelines concerning the diagnostics and therapy of asthma at the primary care level
Updating the guidelines based on new reports and changes in the healthcare system in Poland 
Preparation of lists of reference centres for primary care units in a given region 
Coverage with specialist care of patients with severe, difficult-to-treat asthma
Moderating the collaboration between primary care units and specialist centres
Collaboration with other specialists, regarding the improvement of care of asthmatic patients
Preparation and distribution of informative and educational materials
Organisation of training events, symposia, and conferences devoted to the diagnostics and therapy of asthma  
and presenting the programme’s results
Preparation and support of legislative proposals, building the health-promoting policy of the state, e.g. smoking prohibition 
in public areas
Collaboration with the National Healthcare Fund regarding the improved care of patients suffering from asthma 
Collaboration with the Social Insurance Institution and Employment Agencies, regarding the professional activation  
of asthmatic patients 
Support of patient organisations in the education of patients
Collaboration with media, regarding the popularisation of knowledge on asthma
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results will be performed by the independent Co-
uncil of Programme Course Evaluation, grouping 
experts in epidemiological studies, social, and 
environmental medicine, statisticians, and spe-
cialists involved in the care of asthmatic patients.
Pharmacoeconomic evaluation
Evaluation of the programme results also 
includes pharmacoeconomic parameters with 
direct and indirect costs of the care of patients 
with bronchial asthma. In particular, the expen-
ses will be accounted associated with disability 
pensions, doctor visits, hospital care, and drugs. 
The proportions of expenses in subsequent years 
will be assessed, with changes in the number of 
patients and the degree of the disease severity.
Paediatric programme
Asthma in children has a different course 
and prognoses than asthma in adult patients. Poor 
asthma control is not only a direct threat to health 
and life but it also negatively affects the child’s 
development — physical, motor, psychic, and 
intellectual. Asthma is the most frequent chronic 
disease in children and the most frequent cause 
of their absence at school. Children are much 
more at risk from the side effects of used drugs 
than are adult subjects. Undiagnosed asthma in 
childhood or its unsatisfactory treatment leads 
to the development of severe, therapy-resistant 
asthma in adulthood.
Consequently, it is necessary to develop a se-
parate paediatric programme within the national 
programme, dedicated to this group of patients. 
In the care of children suffering from asthma 
different problems are faced than those observed 
in the care of asthmatic adults. Children are 
often not self-reliant and their treatment requires 
collaboration with parents; therefore, the whole 
family should be involved in the therapeutic pro-
cess. The proper use of inhalation drugs by older 
children is a big problem; therefore, appropriate 
education action should be undertaken, targeted 
both to children and to those adults who control 
the therapy. Another issue is the adherence of 
teenagers to the physician’s recommendations, 
which is the worst among this particular age 
group. Asthmatic children often avoid physical 
exercise for fear of disease symptoms. They are 
exempted from physical training classes, which 
results in their weaker motor development. The-
refore, actions should be undertaken optimising 
the therapy, while also allowing these children 
to partake in physical exercise.
Severe, difficult-to-treat asthma
Severe, difficult-to-treat asthma is the form 
of the disease that is most rare; however, it is 
burdened with the most serious complications 
and worst prognosis. Patients who suffer from 
severe/treatment resistant asthma:
— have low quality of life because of frequent 
symptoms and unexpected exacerbations of 
asthma,
— have limited life activity, they are often una-
ble to perform their work, 
— are particularly exposed to serious adverse 
effects of drugs, especially glucocorticoste-
roids, 
— very often have coexistent diseases, such as 
gastroesophageal reflux and nasal sinusitis. 
In the group of patients with the most severe 
forms of asthma, the following observations were 
made: 
— they have the highest frequency of hospi-
talisations and visits at hospital emergency 
departments, 
— they are at the highest risk level of asthma 
attacks leading to death. 
The annual cost of therapy of a patient with 
severe asthma is several times higher than in 
case of a patient with a mild course of asthma. 
Therefore, these patients require specialist care 
and access to new therapeutic protocols. Such 
patients should obtain complex medical care 
at specialised centres. Complex care of patients 
suffering from severe asthma is at the base of 
the proper approach to these patients, who often 
demonstrate other, coexisting diseases, and the 
effective treatment of these diseases is a con-
dition for general health improvement in the 
patients. These patients are submitted to surgical 
interventions for various indications, to which 
they should be properly prepared, and the drugs 
used by these patients for reasons other than 
asthma may also bias the course of asthma. The-
refore, collaboration among physicians of various 
branches is also important in the management of 
these patients. In the care of these patients, one 
should not forget their psychological problems, 
troubles with work performance, and frequent 
sense of isolation from society because of their 
asthma-related disability.
Programme assumptions for nurses
A properly trained nurse plays an important 
role in the therapy of patient and helps attain 
asthma control. Regarding the physician’s work, 
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the nurse provides invaluable assistance in the 
care of the patient, both at the level of primary 
care in an outpatient clinic or at specialist unit. 
Prior to visiting the doctor, the nurse may eva-
luate the degree of asthma control by means of 
simple tests. The nurse may also recommend an 
additional control visit when worse parameters 
are found or may even recommend only the 
continuation of therapy. It is especially impor-
tant in the practice of primary care physicians, 
where patients very often leave a request for drug 
continuation without having seen the doctor for 
several months. Another stage should comprise 
patient education, covering the issues concerning 
bronchial asthma, the adherence to individual 
treatment programmes, and the management of 
exacerbation cases, as determined earlier by the 
physician, as well as continuous training regar-
ding the inhalation of drugs. 
Programme promotion
This programme has been designed to im-
prove the identifiability of asthma in the early 
stage of disease development and to improve the 
care of patients suffering from asthma. In order to 
obtain these goals the programme will have to be 
accepted by society for which it has been created, 
and by the medical environment in which it plays 
a key role. Therefore, the programme promoting 
activities will be addressed to broad social groups 
and to the medical environment. Information 
will be sent to many people, regarding the needs 
of prophylactics, early diagnosis, and modes of 
therapy, with a particular emphasis on the need 
for proper disease control.
In turn, doctors, nurses, and pharmacists 
will receive information about the epidemio-
logical situation in Poland, the advantages of 
implementation of the programme and specialist 
knowledge concerning the care of asthmatic pa-
tients, specifying their needs. The information 
about the epidemiological situation and needs, 
and regarding the care of asthmatic patients, will 
be provided to the persons who decide about 
health care policy at the national level. For the 
sake of programme promotion, collaboration 
with the media will be undertaken. The applied 
tools will include brochures, releases in everyday 
press and in popular weeklies and monthlies, 
as well as in specialist journals, interviews, and 
radio and TV programmes. Social actions will 
also be undertaken to encourage society to take 
advantage of control examinations, promoting he-
althy lifestyles and health-improving activities. 
Meetings of experts will also be held regarding 
the care of patients suffering from asthma, and of 
persons professionally involved in the national 
healthcare policy.
Summary
The executive summary of the programme 
is presented in Table 4. From the public health 
perspective it is a key issue to implement the best 
available standards of care in everyday practice. 
The asthma burden can be reduced using va-
ried strategies, which can be achieved by local 
efforts, systematic planning, and networking 
to implement the best asthma care [20]. The 
programme is in line with the priorities of the 
Polish Presidency of the Council of the Europe-
an Union, with the main goal to reduce health 
inequalities across societies and to prevent and 
control respiratory diseases in children, adole-
scents, and adults [21]. 
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